Zeiss Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-06-2024
- Paid Up Capital ₹ 0.92 M
as on 04-06-2024
- Company Age 20 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 200.23 Cr
as on 04-06-2024
- Satisfied Charges ₹ 9.83 Cr
as on 04-06-2024
- Revenue -30.54%
(FY 2023)
- Profit -64.01%
(FY 2023)
- Ebitda -56.14%
(FY 2023)
- Net Worth 3.62%
(FY 2023)
- Total Assets -32.63%
(FY 2023)
About Zeiss Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.92 M.
The company currently has active open charges totaling ₹200.23 Cr. The company has closed loans amounting to ₹9.83 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sat Pal, Vikas Gupta, and Vinij Gupta serve as directors at the Company.
- CIN/LLPIN
U24200HP2004PTC026909
- Company No.
026909
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Zeiss Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Gupta  | Director | 11-Mar-2004 | Current |
| Sat Pal | Director | 11-Mar-2004 | Current |
| Vinij Gupta | Director | 11-Mar-2004 | Current |
Financial Performance of Zeiss Pharmaceuticals.
Zeiss Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 30.54% decrease. The company also saw a substantial fall in profitability, with a 64.01% decrease in profit. The company's net worth moved up by a moderate rise of 3.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeiss Pharmaceuticals?
In 2023, Zeiss Pharmaceuticals had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 04 Mar 2024 | ₹10.00 Cr | Open |
Hdfc Bank Limited Creation Date: 10 Feb 2024 | ₹10.00 Cr | Open |
Hdfc Bank Limited Creation Date: 19 Dec 2015 | ₹180.23 Cr | Open |
How Many Employees Work at Zeiss Pharmaceuticals?
Zeiss Pharmaceuticals has a workforce of 101 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeiss Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeiss Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
